DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.99 -0.95%

-$0.16 today

Market cap
$238.98M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.17M

Average 0.24M

DBVT Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

DBV Technologies S.A.NASDAQ: DBVT

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$212.9M, compared with -$613K a year earlier.

Context

  • Net debt amounted to 79.9% of total assets at the end of Q1 FY2026, up 78.7 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -34630.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$212.9M-23.4% QoQ
Last fiscal yearDec 2025
-$172.48M-599.5% YoY
Year agoMar 2025
-$613K-34630.8% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34630.8%——
1 year-599.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(172.48M) USD
Year-over-year change
-599.5%

Net Debt vs competitors

How DBVT compares with its peers on the latest reported figures

  • DBVT's Mar 2026 net debt of -$212.9M is the 9th highest of the 11 companies compared; the peer median is -$94.94M.
  • Its year-over-year change of -34630.8% is the lowest of 11, against a peer median of -61.0%.
  • Net debt amounts to 79.9% of total assets for DBVT, versus a peer median of 25.6%.
DBVT Competitors Peer median
Net Debt for DBVT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$73.6M +305.2%—25.5%
KRROKorro Bio, Inc.Mar 2026-$18.81M +0.8%-45.0%10.2%
ENGNenGene Holdings Inc.Apr 2026-$21.58M +33.0%—7.0%
ALTAltimmune, Inc.Mar 2026-$61.75M -30.0%—18.4%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026-$64.4M -230.0%—25.7%
AMRNAmarin Corporation plcMar 2026-$125.48M -12.5%—19.4%
ANNXAnnexon, Inc.Mar 2026-$149.77M -117.7%—57.0%
LRMRLarimar Therapeutics, Inc.Mar 2026-$174.13M -970.9%—83.5%
DBVTDBV Technologies S.A.Mar 2026-$212.9M -34630.8%—79.9%
ANROAlto Neuroscience, Inc.Mar 2026-$258.07M -92.1%—93.4%
LBRXLB Pharmaceuticals Inc Common StockMar 2026-$317.21M -2931.4%—80.6%
Peer median (excluding DBVT) -$94.94M-61.0%-45.0%25.6%

Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents77.3M209.19M141.37M32.46M194.17M
Short-term Investments00000
Net Receivables33.07M10.49M15.45M10.39M16.15M
Inventory02.68M000
Other Current Assets01K000
Total Current Assets114.52M223.07M158.92M44.39M212.94M
Property, Plant & Equipment (Net)24.92M17.61M17.93M16.81M14.95M
Goodwill0661000
Intangible Assets22K9.34K58K40K22K
Long-term Investments3.97M1.66M3.68M4.31M620K
Tax Assets0(1.66M)000
Other Non-current Assets2.9M5.83M2.4M111K5.19M
Total Non-current Assets31.81M23.44M24.07M21.27M20.78M
Total Assets146.32M246.52M182.99M65.66M233.72M
Account Payables11.43M14.47M23.3M22.03M40.94M
Short-term Debt3.51M1.13M883K846K16.27M
Tax Payables182K69K201.87K188K0
Deferred Revenue4.15M2.14M000
Other Current Liabilities12.13M9.82M11.79M7.42M217K
Total Current Liabilities31.4M29.52M37.34M31.14M58.03M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities8.75M21.42M934K838K1.51M
Total Non-current Liabilities15.9M22.54M5.46M7.14M6.92M
Total Liabilities47.29M52.07M42.8M38.27M64.95M
Common Stock6.54M10.72M10.97M11.65M26.08M
Retained Earnings(98.05M)(259.58M)(238.86M)(286.38M)(393.13M)
Accumulated OCI(15.4M)(13.8M)(8.13M)(12.19M)(5.43M)
Other Stockholders Equity6.14M0000
Minority Interest00000
Total Equity99.03M194.45M140.19M27.39M168.77M
Total Debt10.66M4.15M6.55M7.8M21.68M
Net Debt(66.64M)(205.04M)(134.81M)(24.66M)(172.48M)

DBV Technologies S.A.

NASDAQ:DBVT

Intrinsic Alpha fair value

Locked

Current Price

$9.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.